School of Medicine
Showing 1-10 of 13 Results
-
Emily Chan
Associate Professor of Pathology (Clinical Pathology)
BioDr. Chan is an Associate Professor of Pathology at Stanford University. She completed her MD, PhD at New York University and Anatomic Pathology residency with subspecialty Genitourinary Pathology training at University of California-San Francisco (UCSF). She is AP board-certified. Dr. Chan has been a GU attending at UCSF for the past five years where she has successfully mentored numerous trainees in projects, publications, and career planning. Dr. Chan has co-authored more than 40 peer-reviewed research publications and has a particular interest in integrating molecular testing in diagnostic pathology, as well as recognition of prostate cancer architectural patterns than can help with prognosis and treatment decision making.
-
Howard Y. Chang, MD, PhD
Virginia and D. K. Ludwig Professor of Cancer Research, Professor of Genetics and, by courtesy, of Pathology
Current Research and Scholarly InterestsOur research is focused on how the activities of hundreds or even thousands of genes (gene parties) are coordinated to achieve biological meaning. We have pioneered methods to predict, dissect, and control large-scale gene regulatory programs; these methods have provided insights into human development, cancer, and aging.
-
Vivek Charu
Assistant Professor of Pathology and of Medicine (Quantitative Sciences)
BioI am a physician and a biostatistician. My clinical expertise is in the diagnosis of non-neoplastic kidney and liver disease (including transplantation). My research interests center on the design of observational studies and clinical trials, the analysis of observational data, and causal inference.
-
Greg Charville, MD, PhD
Associate Professor of Pathology
BioDr. Charville has a special interest in the diagnosis of rare tumors that derive from bone and soft tissues, including muscle, fat, blood vessels, cartilage, and other connective tissues. He also specializes in the classification and study of diseases related to the gastrointestinal and hepatopancreatobiliary systems.
Dr. Charville particularly enjoys working alongside Stanford's excellent physicians-in-training to classify the most diagnostically challenging cases in collaboration with pathologists from around the world, bringing to bear cutting-edge techniques for comprehensive histologic and molecular characterization in each case. This experience serves as the inspiration for laboratory-based investigation of the molecular underpinnings of human disease, focusing on genetic and epigenetic mechanisms of neoplasia and the translation of these mechanistic insights into novel diagnostic and predictive biomarkers. -
Michael Cleary
Lindhard Family Professor of Pediatric Cancer Biology and Professor of Pathology, Emeritus
Current Research and Scholarly InterestsThe role of oncoproteins in cancer and development; molecular and cellular biology of hematologic malignancies; targeted molecular therapies of cancer.
-
Maria Inmaculada Cobos Sillero
Associate Professor of Pathology
Current Research and Scholarly InterestsOur lab uses cellular and molecular methods, single-cell technology, and quantitative histology to study human neurodegenerative diseases. Current projects include:
- Using single-cell RNA-sequencing to understand selective vulnerability and disease progression in human Alzheimer’s disease brain
- Investigating mechanisms of tau-related neurodegeneration in human brain
- Studying the neocortical and limbic systems in Diffuse Lewy Body Disease (DLBD) at the single cell level -
Le Cong
Assistant Professor of Pathology (Pathology Research) and of Genetics
Current Research and Scholarly InterestsOur lab develops gene-editing technologies like novel CRISPR systems and large gene insertion techniques for gene&cell therapy. We also leverages these gene-editing tools for single-cell functional screening, to probe molecular mechanisms of cancer and immunological diseases. To accelerate our work, we integrate AI and machine learning to design and evolve gene-editing proteins/RNAs in silico, pushing the frontier that bridges computational and experimental biology.
-
Joanne Cornbleet
Associate Professor of Pathology at the Stanford University Medical Center, Emerita
Current Research and Scholarly InterestsAs medical director of the Hematology Laboratory, my main focus is service work, including laboratory administration, bone marrow pathology, and flow cytometry interpretation. Publications arise primarily from development or evaluation of laboratory methods or collections of unusual patient cases.
-
Helio Costa
Adjunct Clinical Assistant Professor, Pathology
BioHelio Costa, PhD, is a medical geneticist specializing in oncology, genomics, computational biology, data science, artificial intelligence, and product development. His work focuses on developing new cancer therapies and medical software to improve cancer patient care. He currently serves as Senior Medical Director and Head of Molecular Therapeutics & Drug Development at Natera and is an Adjunct Clinical Assistant Professor in the Department of Pathology at Stanford Medical School.
Dr. Costa’s research spans the entire drug development pipeline, from discovery to FDA-approved therapies. He leads efforts in developing innovative cancer treatments by integrating advanced genomics, computational biology, and AI-driven methodologies. His team focuses on the creation of targeted molecular therapeutics, using large-scale genetic data to identify novel treatment pathways and predict patient responses. In addition to drug discovery, Dr. Costa oversees the clinical trials necessary for validating these therapies, ensuring they meet rigorous standards for safety and efficacy. Furthermore, he manages the product development and commercialization process, guiding new treatments from initial research through to market-ready, FDA-approved cancer therapies.
In addition to his therapeutic work, Dr. Costa has led the development and implementation of genetic diagnostic tests and clinical algorithms used to support therapeutic decisions at Stanford Health Care. His contributions include the creation of DNA and RNA cancer diagnostic tests, as well as algorithms that analyze large-scale laboratory datasets and electronic medical records to predict patient outcomes. As a co-investigator with the NIH Clinical Genome Resource (ClinGen) Consortium, Dr. Costa oversaw developing FDA-recognized medical software used by healthcare providers, researchers, and biotech companies to assess the clinical relevance of genes and mutations.
He is the founding director of the Stanford Clinical Data Science Fellowship, where post-doctoral medical fellows engage in interdisciplinary clinical research and implement real-world health data solutions within Stanford Health Care. Dr. Costa is also an Attending Medical Geneticist for the Molecular Genetic Pathology Laboratory at Stanford Health Care, where he previously served as Assistant Lab Director.
Dr. Costa holds a BS in Genetics from the University of California, Davis, a PhD in Genetics from Stanford University School of Medicine, and completed his ABMGG Clinical Molecular Genetics and Genomics fellowship training at Stanford University School of Medicine.
